Full Text
Abstract
Summary. At present, cognitive disorders prevalence of various etiologies increase due to the progressive population aging. An active search continues for biomarkers to be used in daily clinical practice for early diagnosis of diseases manifested by cogni- tive dysfunction, which plays a key role in the development of new treatment and monitoring approaches. Platelets are nuclear-free blood cells with an important role in homeostasis and endothelium functioning. Moreover, platelets have a similar proteomic composition with neurons that allows to estimate them as promising candidates for modeling and evaluating the neurodegener- ative processes. Currently, the possibilities of using the structural and functional platelet parameters for the diagnosis of cognitive disorders, in particular, Alzheimer’s disease, are being actively investigated. This review analyzes the possible use of the main structural and functional platelet parameters as biomarkers of cognitive impairment.
For citation: Kodintcev A.N., Volkova L.I., Antropova I.P., Izmozherova N.V., Popov A.A., Ryabinina A.V. Structural and functional platelet chan- ges in patients with cognitive disorders. Tromboz, gemostaz i reologiya. 2022;(4):4–9. (In Russ.).
References
Holinstat M. Normal platelet function. Cancer Metastasis Rev. 2017;36(2):195–8. DOI: 10.1007/s10555–017–9677-x.
Xu X.R., Zhang D., Oswald B.E. et al. Platelets are versatile cells: new discoveries in hemostasis, thrombosis, immune responses, tumor metastasis and beyond. Crit Rev Clin Lab Sci. 2016;53(6):409– 30. DOI: 10.1080/10408363.2016.1200008.
Canobbio I. Blood platelets: circulating mirrors of neurons? Res Pract Thromb Haemost. 2019;3(4):564–5. DOI: 10.1002/rth2.12254.
Van Nostrand W. E., Schmaier A. H., Farrow J. S., Cunningham D.D. Protease nexin-II (amyloid beta-protein precursor): a platelet alpha-granule protein. Sci
Canobbio I., Visconte C., Momi S. et al. Platelet amyloid precursor protein is a modulator of venous thromboembolism in mice. Blood. 2017;130(4):527–36. DOI: 10.1182/blood-2017–01–764910.
Chacón-Fernández P., Säuberli K., Colzani M. et al. Brainderived neurotrophic factor in megakaryocytes. J Biol Chem. 2016;291(19):9872–81. DOI: 10.1074/jbc.M116.720029.
Amadio P., Porro B., Sandrini L. et al. Patho-physiological role of BDNF in fibrin clotting. Sci Rep. 2019;9(1):389. DOI: 10.1038/ s41598–018–37117–1.
Vasilyeva E. F., Brusov O. S. Platelets, hemostasis and mental disorders. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2019;119(11):103–108. (In Russ.). DOI: 10.17116/jnevro2019119111103.
Kopeikina E., Ponomarev E.D. The role of platelets in the stimulation of neuronal synaptic plasticity, electric activity, and oxidative phosphorylation: possibilities for new therapy of neurodegenerative diseases. Front Cell Neurosci. 2021;15:680126. DOI: 10.3389/fncel. 2021.680126.
Padmakumar M., Van Raes E., Van Geet C. et al. Blood platelet research in autism spectrum disorders: In search of biomarkers. Res Pract Thromb Haemost. 2019;3(4):566–77. DOI: 10.1002/ rth2.12239.
Reed G.L. Platelet secretory mechanisms. Semin Thromb Hemost. 2004;30(4):441–50. DOI: 10.1055/s-2004–833479.
Goubau C., Buyse G.M., Di Michele M. et al. Regulated granule trafficking in platelets and neurons: a common molecular machinery. Eur J Paediatr Neurol. 2013;17(2):117–25. DOI: 10.1016/j.ejpn.2012.08.005.
Rainesalo S., Keränen T., Saransaari P. et al. GABA and glutamate transporters are expressed in human platelets. Brain Res Mol Brain Res. 2005;141(2):161–5. DOI: 10.1016/j.molbrainres.2005.08.013.
Fleury S., Boukhatem I., Le Blanc J. et al. Tissue-specificity of antibodies raised against TrkB and p75NTR receptors; implications for platelets as models of neurodegenerative diseases. Front Immunol. 2021;12:606861. DOI: 10.3389/fimmu.2021.606861.
Pluta R., Ułamek-Kozioł M., Januszewski S. et al. Platelets, lymphocytes and erythrocytes from Alzheimer’s disease patients: the quest for blood cell-based biomarkers. Folia Neuropathol. 2018;56(1):14–20. DOI: 10.5114/fn.2018.74655.
Gowert N.S., Donner L., Chatterjee M. et al. Blood platelets in the progression of Alzheimer’s disease. PLoS One. 2014;9(2):e90523. DOI: 10.1371/journal.pone.0090523.
Donner L., Fälker K., Gremer L. et al. Platelets contribute to amyloid-β aggregation in cerebral vessels through integrin αIIbβ3-induced outside-in signaling and clusterin release. Sci Signal. 2016;9(429):ra52. DOI: 10.1126/scisignal.aaf6240.
BarbourR.,KlingK.,AndersonJ.P.etal.Redbloodcellsarethe major source of alpha-synuclein in blood. Neurodegener Dis. 2008;5(2):55–9. DOI: 10.1159/000112832.
Akingbade O.E.S., Gibson C., Kalaria R.N. et al. Platelets: peripheral biomarkers of dementia? J Alzheimers Dis. 2018;63(4):1235–59. DOI: 10.3233/JAD-180181.
Ramdane S. Lower platelet count and decreased mean platelet volume in patients with Alzheimer’s disease. Alzheimer’s & Dementia. 2019;15(7):P1350. DOI: 10.1016/j.jalz.2019.06.3853.
Dos Santos G.A.A., Pardi P.C. Biomarkers in Alzheimer’s disease: evaluation of platelets, hemoglobin and vitamin B12. Dement Neuropsychol. 2020;14(1):35–40. DOI: 10.1590/1980–57642020dn14– 010006.
Espinosa-Parrilla Y., Gonzalez-Billault C., Fuentes E. et al. Decoding the role of platelets and related microRNAs in aging and neurodegenerative disorders. Front Aging Neurosci. 2019;11:151. DOI: 10.3389/fnagi.2019.00151.
Zhao S., Zhao J., Zhang T. et al. Increased apoptosis in the platelets of patients with Alzheimer’s disease and amnestic mild cognitive impairment. Clin Neurol Neurosurg. 2016;143:46–50. DOI: 10.1016/j.clineuro. 2016.02.015.
Sun D., Wang Q., Kang J. et al. Correlation between serum platelet count and cognitive function in patients with atrial fibrillation: a cross-sectional study. Cardiol Res Pract. 2021;2021:9039610. DOI: 10.1155/2021/9039610.
Prodan C. I., Ross E. D., Stoner J. A. et al. Coated-platelet levels and progression from mild cognitive impairment to Alzheimer disease. Neurology. 2011;76(3):247–52. DOI: 10.1212/ WNL.0b013e3182074bd2.
Aliotta A., Calderara D.B., Zermatten M.G. et al. Sodium-calcium exchanger reverse mode sustains dichotomous ion fluxes required for procoagulant COAT platelet formation. Thromb Haemost. 2021;121(3):309–21. DOI: 10.1055/s-0040–171670.
Prodan C.I., Szasz R., Vincent A.S. et al. Coated-platelets retain amyloid precursor protein on their surface. Platelets. 2006;17(1):56– 60. DOI: 10.1080/09537100500181913.
Wang R.T., Jin D., Li Y. et al. Decreased mean platelet volume and platelet distribution width are associated with mild cognitive impairment and Alzheimer’s disease. J Psychiatr Res. 2013;47(5):644–9. DOI: 10.1016/j.jpsychires.2013.01.014.
Liang Q.C., Jin D., Li Y. et al. Mean platelet volume and platelet distribution width in vascular dementia and Alzheimer’s disease. Platelets. 2014;25(6):433–8. DOI: 10.3109/09537104.2013.831064.
ChenS.H., BuX.L., JinW.S. et al. Altered peripheral profile of blood cells in Alzheimer disease: a hospital-based case-control study. Medicine (Baltimore). 2017;96(21): e6843. DOI: 10.1097/ MD.0000000000006843.
Yesil Y., Kuyumcu M.E., Cankurtaran M. et al. Increased mean platelet volume (MPV) indicating the vascular risk in Alzheimer’s disease (AD). Arch Gerontol Geriatr. 2012;55(2):257–60. DOI: 10.1016/j.archger.2011.09.016.
Koç E.R., Uzar E., Çirak Y. et al. The increase of mean platelet volume in patients with Alzheimer disease. Turk J Med Sci. 2014;44(6):1060–6. DOI: 10.3906/sag-1212–5.
Dong X., Nao J., Shi J. et al. Predictive value of routine peripheral blood biomarkers in Alzheimer’s disease. Front Aging Neurosci. 2019;11:332. DOI: 10.3389/fnagi.2019.00332.
Stellos K., Panagiota V., Kögel A. et al. Predictive value of platelet activation for the rate of cognitive decline in Alzheimer’s disease patients. J Cereb Blood Flow Metab. 2010;30(11):1817–20. DOI: 10.1038/jcbfm.2010.140.
Stellos K., Katsiki N., Tatsidou P. et al. Association of platelet activation with vascular cognitive impairment: implications in dementia development? Curr Vasc Pharmacol. 2014;12(1):152–4. DOI: 10.2174/157016111201140327164641.
Cho K., Kim J., Kim G.W. Changes in blood factors and ultrasound findings in mild cognitive impairment and dementia. Front Aging Neurosci. 2017;9:427. DOI: 10.3389/fnagi.2017.00427.
Kuriyama N., Mizuno T., Yasuike H. et al. CD62-mediated activation of platelets in cerebral white matter lesions in patients with cognitive decline. Arch Gerontol Geriatr. 2016;62:118–24. DOI: 10.1016/j.archger.2015.09.001.
Järemo P., Milovanovic M., Buller C. et al. P-selectin paradox and dementia of the Alzheimer type: circulating P-selectin is increased but platelet-bound P-selectin after agonist provocation is compromised. Scand J Clin Lab Invest. 2013;73(2):170–4. DOI: 10.3109/00365513.2013.764572.
Bélanger J.C., Bouchard V., Le Blanc J. et al. Brain-derived neurotrophic factor mitigates the association between platelet dysfunction and cognitive impairment. Front Cardiovasc Med. 2021;8:739045. DOI: 10.3389/fcvm.2021.739045.